Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| IMS Company Profiles:Amgen | Feb 2011 | £640 | 100% |
| Pharma Company Profiles - Amgen | Oct 2008 | £255 | 99% |
| Amgen Inc.-Therapeutic Competitors | Mar 2011 | £220 | 99% |
| Amgen Profile, Patents and Pipeline |
Aug 2005 | £315 | 99% |
| Amgen Inc.-Detailed Product Pipeline | Mar 2011 | £475 | 99% |
| Amgen Limited-Therapeutic Competitors Report | Mar 2011 | £220 | 99% |
| Amgen B.V.-Therapeutic Competitors Report | Mar 2011 | £220 | 99% |
| Amgen Inc. - Medical Equipment Deals and Alliances Profile |
Jul 2009 | £160 | 99% |
| Amgen - Product Pipeline Review Q4 2010 |
Nov 2010 | £315 | 99% |
| Amgen Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 98% |
| Amgen Australia Pty Ltd.-Therapeutic Competitors Report | Mar 2011 | £220 | 98% |
| Partnering Agreements with Amgen 2010 | Jan 2010 | £630 | 98% |
| Amgen Inc.-Deals & Alliances Report | Mar 2011 | £380 | 98% |
| Amgen: Pipeline • Products • Performance • Potential | Nov 2010 | £595 | 97% |
| Amgen Inc.: PharmaVitae Profile Healthcare |
Mar 2009 | £3,605 | 97% |
| Top 10 Biotech Companies Market Outlook, 2008-2023 |
Jan 2009 | £1,499 | 90% |
| Biotechnology in Canada | Sep 2011 | £160 | 88% |
| Top 10 Biotechnology Companies SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline |
Feb 2010 | £2,215 | 88% |
| Monoclonal Antibodies Report Part II Companies - Holding Mabs In Portfolio Promises Protection Against The Looming 2011-12 Patent Cliff |
Sep 2007 | £4,805 | 87% |
| Biotechnology in the United States | Sep 2011 | £160 | 87% |
| Biotechnology Industry 2010 Yearbook Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions |
Dec 2010 | £2,215 | 84% |
| World Biological Drugs Market 2011-2021 |
Feb 2011 | £1,499 | 83% |
| Post Menopausal Osteoporosis - Pipeline Review H2 2011 |
Aug 2011 | £315 | 82% |
| Bone Metastases Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Apr 2011 | £1,265 | 82% |
| Global Biosimilars A return to optimism? |
Jan 2012 | £1,295 | 82% |
| Maxygen, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 82% |
| Thrombocytopenia Global Clinical Trials Review Q1, 2011 |
Apr 2011 | £630 | 82% |
| Rheumatoid Arthritis: World Drug Market 2011-2021 |
Sep 2011 | £1,699 | 81% |
| Anemia Global Clinical Trials Review Q1, 2011 |
Jan 2011 | £630 | 81% |
| Cancer Market Trends 2008 - 2012 | Jan 2009 | £1,100 | 81% |
